The DOI matches its Crossref record; 8 of the 8 references it cites were found in a registry or an index.
Changes in lipoprotein kinetics during therapy with fenofibrate and other fibric acid derivatives
Abstract
The fibric acid derivatives, including fenofibrate, significantly reduce very low-density lipoprotein triglyceride concentrations by stimulating lipoprotein lipase activity, thereby increasing very low-density lipoprotein catabolism. These agents may also reduce the hepatic secretion of nascent very low-density lipoprotein, but this effect is less consistent. Effects on low-density lipoprotein metabolism appear to depend upon the lipid disorder present before therapy. If hypertriglyceridemia and normal or low low-density lipoprotein levels are present, fibrate therapy is associated with a rise in low-density lipoprotein levels. This is due to a decreased fractional catabolism of low-density lipoprotein from an unusually high clearance to a more normal value. Treating pre-existing hypercholesterolemia usually results in a significant decrease in low-density lipoprotein levels. In this disorder, there is a demonstrable increase in low-density lipoprotein receptor-mediated clearance. It is not known at which site these drugs act to increase low-density lipoprotein receptor function in the latter patients. Some studies suggest that fibrate therapy increases high-density lipoprotein apolipoprotein AI production, but how this occurs has not been defined.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“although the findings regarding the latter effect of PPARα agonism are less consistent than those regarding increases in the activity of lipoprotein lipase. 17-19”
From Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk (2022) · cites this paper as [17]
Citations
Cites
Mechanism of action of gemfibrozil on lipoprotein metabolism.
Saku, K., Gartside, P. S., Hynd, B. A., & Kashyap, M. L. (1985) · Journal of Clinical Investigation · doi:10.1172/jci111879 · Cited by 182
Influence of Gemfibrozil and Clofibrate on Metabolism of Cholesterol and Plasma Triglycerides in Man
Kesäniemi, Y. A. (1984) · JAMA · doi:10.1001/jama.1984.03340410049031 · Cited by 165
Stewart, J. M., Packard, C. J., Lorimer, A. R., Boag, D. E., & Shepherd, J. (1982) · Atherosclerosis · doi:10.1016/0021-9150(82)90010-7 · Cited by 103
Fenofibrate reduces low density lipoprotein catabolism in hypertriglyceridemic subjects.
Shepherd, J., CASLAKE, M. J., Lorimer, A. R., Vallance, B. D., & Packard, C. J. (1985) · Arteriosclerosis An Official Journal of the American Heart Association Inc · doi:10.1161/01.atv.5.2.162 · Cited by 96
Malmendier, C. L., & Delcroix, C. (1985) · Atherosclerosis · doi:10.1016/0021-9150(85)90095-4 · Cited by 85
Shepherd, J., Packard, C. J., Stewart, J. M., Atmeh, R. F., Clark, R., Boag, D. E., Carr, K., Lorimer, A. R., Ballantyne, D., & Morgan, H. (1984) · Journal of Clinical Investigation · doi:10.1172/jci111643 · Cited by 85
Gemfibrozil Therapy in Primary Hypertriglyceridemia Associated With Coronary Heart Disease
Vega, G. L. (1985) · JAMA · doi:10.1001/jama.253.16.2398 · Cited by 72
Effects of bezafibrate on apolipoprotein B metabolism in type III hyperlipoproteinemic subjects.
Packard, C. J., Clegg, R. J., Dominiczak, M. H., Lorimer, A. R., & Shepherd, J. (1990) · Journal of Lipid Research · doi:10.1016/s0022-2275(20)38775-7 · Cited by 54
Cited by
Sorted by citations
Ginsberg, H. N., Packard, C. J., Chapman, M. J., Borén, J., Aguilar-Salinas, C. A., Averna, M., Ference, B. A., Gaudet, D., Hegele, R. A., Kersten, S., et al. (2021) · European Heart Journal · doi:10.1093/eurheartj/ehab551 · Cited by 979
“163,164 Guideline-recommended first steps for managing hypertrigly-ceridaemia are diet modification and weight loss.”
BackgroundSelf-citationAoyama, T., Peters, J. M., Iritani, N., Nakajima, T., Furihata, K., Hashimoto, T., & Gonzalez, F. J. (1998) · Journal of Biological Chemistry · doi:10.1074/jbc.273.10.5678 · Cited by 867
Triglyceride Lowering with Pemafibrate to Reduce Cardiovascular Risk
Das Pradhan, A., Glynn, R. J., Fruchart, J.-C., MacFadyen, J. G., Zaharris, E. S., Everett, B. M., Campbell, S. E., Oshima, R., Amarenco, P., Blom, D. J., et al. (2022) · New England Journal of Medicine · doi:10.1056/nejmoa2210645 · Cited by 749
Self-citationCauses and consequences of hypertriglyceridemia
Packard, C. J., Boren, J., & Taskinen, M.-R. (2020) · Frontiers in Endocrinology · doi:10.3389/fendo.2020.00252 · Cited by 239
“In individuals with initially low plasma triglyceride, fenofibrate therapy caused LDL cholesterol and apoB concentrations to fall by 10–20% (49, 50, 105) due to an increased clearance rate.”
BackgroundBalfour, J. A. B., McTavish, D., & Heel, R. C. (1990) · Drugs · doi:10.2165/00003495-199040020-00007 · Cited by 203
Gut-liver interaction in triglyceride-rich lipoprotein metabolism
Xiao, C., Hsieh, J., Adeli, K., & Lewis, G. F. (2011) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00178.2011 · Cited by 131
“Following a meal, the majority of the chylomicron TG is sequestered by extrahepatic tissues (mainly adipose) following LPL lipolysis in the capillary microcirculation (19, 175).”
BackgroundInfluentialThe effect of PPAR-α agonism on apolipoprotein metabolism in humans
Shah, A., Rader, D. J., & Millar, J. S. (2009) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2009.11.010 · Cited by 124
Triglyceride-Rich Lipoprotein Remnants and Cardiovascular Disease
Duran, E. K., & Pradhan, A. D. (2020) · Clinical Chemistry · doi:10.1093/clinchem/hvaa296 · Cited by 108
Najib, J. S. (2002) · Clinical Therapeutics · doi:10.1016/s0149-2918(02)80095-9 · Cited by 85
Effects of atorvastatin versus fenofibrate on apoB-100 and apoA-I kinetics in mixed hyperlipidemia
Bilz, S., Wagner, S., Schmitz, M., Bedynek, A., Keller, U. B., & Demant, T. (2004) · Journal of Lipid Research · doi:10.1194/jlr.m300309-jlr200 · Cited by 83
Effects of Gemfibrozil and Other Fibric Acid Derivatives on Blood Lipids and Lipoproteins
ZIMETBAUM, P. J., Frishman, W. H., & Kahn, S. (1991) · The Journal of Clinical Pharmacology · doi:10.1002/j.1552-4604.1991.tb01883.x · Cited by 78
Fenofibrate lowers lipid accumulation in myotubes by modulating the PPARα/AMPK/FoxO1/ATGL pathway
Chen, W.-L., Chen, Y., Chiang, Y.-M., Wang, S.-G., & Lee, H.-M. (2012) · Biochemical Pharmacology · doi:10.1016/j.bcp.2012.05.022 · Cited by 74
The effects of fibrates on lipoprotein and hemostatic coronary risk factors.
Schonfeld, G. (1994) · Atherosclerosis · doi:10.1016/0021-9150(94)90090-6 · Cited by 78
Micronized Fenofibrate: A New Fibric Acid Hypolipidemic Agent
Guay, D. R. P. (1999) · Annals of Pharmacotherapy · doi:10.1345/aph.18432 · Cited by 69
Ståhlberg, D., Reihnér, E., Rudling, M. J., Berglund, L., Einarsson, K., & Angelin, B. (1995) · Hepatology · doi:10.1002/hep.1840210421 · Cited by 67
Role of fibrates in cardiovascular disease prevention, the ACCORD-Lipid perspective
Elam, M. B., Lovato, L., & Ginsberg, H. N. (2010) · Current Opinion in Lipidology · doi:10.1097/mol.0b013e328341a5a8 · Cited by 56
Self-citationParhofer, K. G., & Barrett, P. H. R. (2006) · Journal of Lipid Research · doi:10.1194/jlr.r600013-jlr200 · Cited by 56
“Peroxisome proliferator-activated receptor a agonists, such as fibrates, primarily increase the catabolism of VLDL-, IDL-, and LDL-apoB, whereas they seem to have little effect on the hepatic secretion of lipoproteins (79), although earlier studies performed with exogenously radiolabeled lipoproteins indicated that fi…”
Fenofibrate, HDL, and cardiovascular disease in Type-2 diabetes: The DAIS trial
Tsunoda, F., Asztalos, I. B., Horvath, K. V., Steiner, G. A., Schaefer, E. J., & Asztalos, B. F. (2016) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2016.01.028 · Cited by 40
“The increased LPL activity accelerates the catabolism of VLDL to IDL and subsequently LDL [24].”
Potential use of fenofibrate and other fibric acid derivatives in the clinic
Brown, W. V. (1987) · The American Journal of Medicine · doi:10.1016/0002-9343(87)90876-x · Cited by 31
Kłosiewicz−Latoszek, L., & Szostak, W. B. (1991) · European Journal of Clinical Pharmacology · doi:10.1007/bf00315136 · Cited by 31
Chapman, M. J., Packard, C. J., Björnson, E., Ginsberg, H. N., & Borén, J. (2025) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2025.120529 · Cited by 36
Self-citationCatalposide is a natural agonistic ligand of peroxisome proliferator-activated receptor-α
Lee, J. H., Jun, H., Hoang, M.-H., Jia, Y., Han, X. H., Lee, D., Lee, H.-J., Hwang, B. Y., & Lee, S. (2012) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2012.05.025 · Cited by 13
“Activation of PPARa increases lipolysis and the elimination of TG-rich particles from plasma by activating lipoprotein lipase [15] and may induce HDL particle production, by stimulating apolipoprotein A1 (ApoA1) gene expression leading to more HDL particles [16].”
BackgroundInvited Review: Lipoprotein Lipase and Triglyceride‐Rich Lipoprotein Metabolism
Miles, J. M., Park, Y., & Harris, W. S. (2001) · Nutrition in Clinical Practice · doi:10.1177/088453360101600502 · Cited by 11
Ginsberg, H. N., & Bornfeldt, K. (2026) · Circulation Research · doi:10.1161/circresaha.125.327267 · Cited by 4
Self-citationBaragetti, A. (2022) · Metabolism and Target Organ Damage · doi:10.20517/mtod.2022.09 · Cited by 4
Isotopic Tracers for the Measurement of Metabolic Flux Rates
Beysen, C., Hellerstein, M. K., & Turner, S. (2014) · Springer eBooks · doi:10.1007/978-1-4471-4920-0_3 · Cited by 4
2 Practical drug therapy for common hyperlipidaemias
Tikkanen, M. J. (1990) · Baillière s Clinical Endocrinology and Metabolism · doi:10.1016/s0950-351x(05)80077-1 · Cited by 4
Pharmacoeconomic Evaluation of Anti-Hyperlipidemic Agent Fenofibrate
Hayakawa, T., Shimoyama, K., Sekiya, S., SEKIGUCHI, M., & Inotsume, N. (2002) · YAKUGAKU ZASSHI · doi:10.1248/yakushi.122.1145 · Cited by 1
Isotopic Tracers for the Measurement of Metabolic Flux Rates
Beysen, C., Angel, T. E., Hellerstein, M. K., & Turner, S. (2019) · Springer eBooks · doi:10.1007/978-3-030-11748-1_9 · Cited by 2
Quantifying protein kinetics in vivo: influence of precursor dynamics on product labeling
Yao, H., Kelley, S., Zhou, D., VanSickle, S., Wang, S., Piesvaux, J., Zhou, H., Chen, H., McKenney, D., McLaren, D. G., et al. (2024) · American Journal of Physiology-Endocrinology and Metabolism · doi:10.1152/ajpendo.00323.2024
Coan, A. C. C., Katsuyama, E. S., Lopes, R. A., Sanchez, C. V., Prata, A. A., Fukunaga, C. K., Talavera, A., & Shapiro, M. D. (2026) · Journal of Pharmacology and Experimental Therapeutics · doi:10.1016/j.jpet.2026.105022
Metadata
- Authors
- Ginsberg, H. N.
- Affiliations
- Columbia University (US)
- Corresponding author
- Ginsberg, Henry N.
- ORCID
- Ginsberg, Henry N.
- Venue
- The American Journal of Medicine
- Publisher
- Elsevier BV
- Published
- 1987-11
- Volume
- 83
- Issue
- 5
- Pages
- 66-70
- ISSN
- 0002-9343 (ISSN-L)
- OpenAlex
- W1980196562
- Cited by
- 32
- References
- 8
- Citations by year
- 2026: 2 · 2025: 1 · 2024: 1 · 2022: 2 · 2021: 1 · 2020: 2 · 2019: 2 · 2016: 1 · 2014: 1 · 2012: 2
- FWCI
- 1.01
- Type
- journal article
- Language
- en
- Open access
- closed
- Locations
- The American Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipid metabolism and disorders
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
- Keywords
- fenofibrate, fibrates, lipoprotein kinetics, VLDL, low-density lipoprotein, high-density lipoprotein, lipoprotein lipase, hepatic VLDL secretion, hypertriglyceridemia, hypercholesterolemia, apolipoprotein A-I, lipid-lowering therapy
- MeSH terms
- Anticholesteremic Agents, Apolipoproteins, Clofibrate, Humans, Kinetics, Lipoprotein Lipase, Lipoproteins, Lipoproteins, HDL, Lipoproteins, LDL, Lipoproteins, VLDL, Fenofibrate, Propionates
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
